Results 211 to 220 of about 3,775,993 (302)

Preferences for Tapering Biologic Disease-Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment. [PDF]

Arthritis Care Res (Hoboken)
Chan SJ, Stamp LK, Treharne GJ, Cheung JMY, Dalbeth N, Grainger R, Stebbings S, Marra CA.   +7 more
europepmc   +1 more source

Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease‐modifying antirheumatic drugs

International Journal of Rheumatic Diseases, 2016
J. Nakamura, T. Nagashima, K. Nagatani, T. Yoshio, M. Iwamoto, S. Minota   +5 more
semanticscholar   +1 more source

Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network. [PDF]

Front Pharmacol
Vitale A, Leone F, Caggiano V, Hinojosa-Azaola A, Martín-Nares E, Guaracha-Basañez GA, Torres-Ruiz J, Ayumi Kawakami-Campos P, Hissaria P, Callisto A, Beecher M, Dagna L, Tomelleri A, Campochiaro C, Frassi M, Crisafulli F, Franceschini F, Hernández-Rodríguez J, Gómez-Caverzaschi V, Araújo O, Sfriso P, Bindoli S, Baggio C, Sbalchiero J, Sota J, Tufan A, Vasi I, Piga M, Cauli A, D'Agostino MA, De Paulis A, Mormile I, Mayrink Giardini HA, Cordeiro RA, Gavioli F, Lopalco G, Iannone F, Montecucco C, Monti S, Ruiz-Irastorza G, Soto-Peleteiro A, Triggianese P, Gurnari C, Viapiana O, Bixio R, Vitetta R, Conticini E, La Torre F, Ragab G, Batu ED, González-García A, Peña-Rodríguez M, Bocchia M, Wiesik-Szewczyk E, Jahnz-Rózyk K, de-la-Torre A, Balistreri A, Frediani B, Fabiani C, Cantarini L.   +59 more
europepmc   +1 more source

Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease. [PDF]

J Clin Med
Kawczak P, Feszak IJ, Bączek T.
europepmc   +1 more source

Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database. [PDF]

Front Pharmacol
Xiong W, Li Y, Hu L, He G, Huang J.
europepmc   +1 more source

Trends in New Use of Disease-Modifying Antirheumatic Drugs for Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001 to 2022. [PDF]

Arthritis Rheumatol
Yalamanchili P, Lee LY, Bushnell G, Mannion ML, Dave CV, Horton DB.   +5 more
europepmc   +1 more source

Complications of invasive oral procedures in patients with immune-mediated inflammatory disorders treated with biological and conventional disease-modifying antirheumatic drugs or glucocorticoids: a scoping review of the literature. [PDF]

BMC Oral Health
Radoi L, Kadri M, Gosset M.
europepmc   +1 more source

The marked and rapid therapeutic effect of tofacitinib in combination with subcutaneous methotrexate in a rheumatoid arthritis patient with poor prognostic factors who is resistant to standard disease-modifying antirheumatic drugs and biologicals: A clinical case

, 2016
Н. В. Демидова, Е. Л. Лучихина, Д. Е. Каратеев   +2 more
openalex   +2 more sources

Letter to the Editor Regarding: "Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry". [PDF]

Rheumatol Ther
Liu Z, Tian M, Duan L.
europepmc   +1 more source

Factors predicting treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review and meta-analysis. [PDF]

Clin Rheumatol
Künzler T, Bamert M, Sprott H.
europepmc   +1 more source